{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "gene therapy", "nanomedicines", "neurofibrillary tangles", "nutraceuticals", "pathophysiology", "phytopharmaceuticals"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35956796", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "15"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "28"}], "Language": ["eng"], "ELocationID": ["4839", "10.3390/molecules27154839"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "15", "PubDate": {"Year": "2022", "Month": "Jul", "Day": "28"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.", "Abstract": {"AbstractText": ["Alzheimer's disease (AD) is a chronic dysfunction of neurons in the brain leading to dementia. It is characterized by gradual mental failure, abnormal cognitive functioning, personality changes, diminished verbal fluency, and speech impairment. It is caused by neuronal injury in the cerebral cortex and hippocampal area of the brain. The number of individuals with AD is growing at a quick rate. The pathology behind AD is the progress of intraneuronal fibrillary tangles, accumulation of amyloid plaque, loss of cholinergic neurons, and decrease in choline acetyltransferase. Unfortunately, AD cannot be cured, but its progression can be delayed. Various FDA-approved inhibitors of cholinesterase enzyme such as rivastigmine, galantamine, donepezil, and NDMA receptor inhibitors (memantine), are available to manage the symptoms of AD. An exhaustive literature survey was carried out using SciFinder's reports from Alzheimer's Association, PubMed, and Clinical Trials.org. The literature was explored thoroughly to obtain information on the various available strategies to prevent AD. In the context of the present scenario, several strategies are being tried including the clinical trials for the treatment of AD. We have discussed pathophysiology, various targets, FDA-approved drugs, and various drugs in clinical trials against AD. The goal of this study is to shed light on current developments and treatment options, utilizing phytopharmaceuticals, nanomedicines, nutraceuticals, and gene therapy."]}, "AuthorList": [{"Identifier": ["0000-0003-1809-9232"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Synthetic Unit, Department of Photochemistry, Chemical Industries Research Institute, National Research Centre, Cairo 12622, Egypt."}], "LastName": "Hassan", "ForeName": "Nasser A", "Initials": "NA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, College of Science, Ha'il University, Ha'il 81451, Saudi Arabia."}], "LastName": "Alshamari", "ForeName": "Asma K", "Initials": "AK"}, {"Identifier": ["0000-0002-3123-1026"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, Suez University, Suez 43221, Egypt."}, {"Identifier": [], "Affiliation": "Department of Chemistry, College of Science, Shaqra University, Shaqra 11961, Saudi Arabia."}], "LastName": "Hassan", "ForeName": "Allam A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Basic Medical Sciences, College of Medicine, Shaqra University, Shaqra 11961, Saudi Arabia."}], "LastName": "Elharrif", "ForeName": "Mohamed G", "Initials": "MG"}, {"Identifier": ["0000-0003-2978-1042"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia."}], "LastName": "Alhajri", "ForeName": "Abdullah M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia."}], "LastName": "Sattam", "ForeName": "Mohammed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Synthetic Unit, Department of Photochemistry, Chemical Industries Research Institute, National Research Centre, Cairo 12622, Egypt."}], "LastName": "Khattab", "ForeName": "Reham R", "Initials": "RR"}], "GrantList": [{"GrantID": "IFP2021- 095", "Agency": "Deputyship for Research &amp; Innovation, Ministry of Education in Saudi Arabia", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cholinesterase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Indans"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperidines"}, {"RegistryNumber": "PKI06M3IW0", "NameOfSubstance": "Rivastigmine"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cholinesterase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Indans"}, {"QualifierName": [], "DescriptorName": "Nanotechnology"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Piperidines"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Rivastigmine"}], "CoiStatement": "The authors declare no conflict of interest, financial or otherwise."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet. Med. 2016;18:421\u2013430. doi: 10.1038/gim.2015.117.", "ArticleIdList": ["10.1038/gim.2015.117", "PMC4857183", "26312828"]}, {"Citation": "Prasansuklab A., Tencomnao T. Amyloidosis in Alzheimer\u2019s disease: The Toxicity of Amyloid Beta (A\u03b2), Mechanisms of Its Accumulation and Implications of Medicinal Plants for Therapy. Evid.-Based Complement. Altern. Med. 2013;2013:413808. doi: 10.1155/2013/413808.", "ArticleIdList": ["10.1155/2013/413808", "PMC3671299", "23762130"]}, {"Citation": "Bird T.D. GeneReviews. University of Washington; Seattle, WA, USA: 2012. Early-onset familial Alzheimer\u2019s disease; pp. 1\u201342.", "ArticleIdList": ["20301414"]}, {"Citation": "Chu L.W. Alzheimer\u2019s disease: Early diagnosis and treatment. Hong Kong Med. J. 2012;18:228\u2013237.", "ArticleIdList": ["22665688"]}, {"Citation": "Sun X., Chen W.-D., Wang Y.-D. \u03b2-Amyloid: The key peptide in the pathogenesis of Alzheimer\u2019s disease. Front. Pharmacol. 2015;6:221. doi: 10.3389/fphar.2015.00221.", "ArticleIdList": ["10.3389/fphar.2015.00221", "PMC4588032", "26483691"]}, {"Citation": "Cervellati C., Wood P.L., Romani A., Valacchi G., Squerzanti M., Sanz J.M., Ortolani B., Zuliani G. Oxidative challenge in Alzheimer\u2019s disease: State of knowledge and future needs. J. Investig. Med. 2016;64:21\u201332. doi: 10.1136/jim-2015-000017.", "ArticleIdList": ["10.1136/jim-2015-000017", "26755810"]}, {"Citation": "Sharma K. Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. Mol. Med. Rep. 2019;20:1479\u20131487. doi: 10.3892/mmr.2019.10374.", "ArticleIdList": ["10.3892/mmr.2019.10374", "PMC6625431", "31257471"]}, {"Citation": "Lipton S.A., Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium. 1998;23:165\u2013171. doi: 10.1016/S0143-4160(98)90115-4.", "ArticleIdList": ["10.1016/S0143-4160(98)90115-4", "9601612"]}, {"Citation": "Fish P.V., Steadman D., Bayle E.D., Whiting P. New approaches for the treatment of Alzheimer\u2019s disease. Bioorg. Med. Chem. Lett. 2018;29:125\u2013133. doi: 10.1016/j.bmcl.2018.11.034.", "ArticleIdList": ["10.1016/j.bmcl.2018.11.034", "30501965"]}, {"Citation": "Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., Burns A., Dening T., Findlay D., Holmes C., et al. Donepezil and Memantine for Moderate-to-Severe Alzheimer\u2019s disease. N. Engl. J. Med. 2012;366:893\u2013903. doi: 10.1056/NEJMoa1106668.", "ArticleIdList": ["10.1056/NEJMoa1106668", "22397651"]}, {"Citation": "Farlow M., Anand R., Messina J., Jr., Hartman R., Veach J. A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer\u2019s disease. Eur. Neurol. 2000;44:236\u2013241. doi: 10.1159/000008243.", "ArticleIdList": ["10.1159/000008243", "11096224"]}, {"Citation": "Tripathi A.C., Saraf S.A., Saraf S.K., Tripathi A.C., Saraf S.A., Saraf S.K. Carbon Nanotropes: A Contemporary Paradigm in Drug Delivery. Materials. 2015;8:3068\u20133100. doi: 10.3390/ma8063068.", "ArticleIdList": ["10.3390/ma8063068"]}, {"Citation": "Cummings J., Lee G., Mortsdorf T., Ritter A., Zhong K. Alzheimer\u2019s disease drug development pipeline: 2017. Alzheimer\u2019s Dementia Transl. Res. Clin. Interv. 2017;3:367\u2013384. doi: 10.1016/j.trci.2017.05.002.", "ArticleIdList": ["10.1016/j.trci.2017.05.002", "PMC5651419", "29067343"]}, {"Citation": "Rayathala J., Kumar K., Venkatesh P. Review on Alzheimer\u2019s disease: Past, present and future. J. Innov. Appl. Pharm. Sci. 2022;7:28\u201331. doi: 10.37022/jiaps.v7i1.274.", "ArticleIdList": ["10.37022/jiaps.v7i1.274"]}, {"Citation": "Cipriani G., Dolciotti C., Picchi L., Bonuccelli U. Alzheimer and his disease: A brief history. Neurol. Sci. 2010;32:275\u2013279. doi: 10.1007/s10072-010-0454-7.", "ArticleIdList": ["10.1007/s10072-010-0454-7", "21153601"]}, {"Citation": "Kumar A., Sidhu J., Goyal A.  StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2020.  [(accessed on 8 December 2020)]. Alzheimer Disease. Available online:  https://www.ncbi.nlm.nih.gov/books/NBK499922/"}, {"Citation": "Wattmo C., Minthon L., Wallin K. Mild versus moderate stages of Alzheimer\u2019s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimer\u2019s Res. Ther. 2016;8:7. doi: 10.1186/s13195-016-0174-1.", "ArticleIdList": ["10.1186/s13195-016-0174-1", "PMC4756534", "26883213"]}, {"Citation": "Apostolova L.G. Alzheimer Disease. Contin. Lifelong Learn. Neurol. 2016;22:419\u2013434. doi: 10.1212/CON.0000000000000307.", "ArticleIdList": ["10.1212/CON.0000000000000307", "PMC5390933", "27042902"]}, {"Citation": "Armstrong R.A. Risk factors for Alzheimer\u2019s disease. Folia Neuropathol. 2019;57:87\u2013105. doi: 10.5114/fn.2019.85929.", "ArticleIdList": ["10.5114/fn.2019.85929", "31556570"]}, {"Citation": "Anand P., Singh B. A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch. Pharmacal Res. 2013;36:375\u2013399. doi: 10.1007/s12272-013-0036-3.", "ArticleIdList": ["10.1007/s12272-013-0036-3", "23435942"]}, {"Citation": "Blass J.P. Alzheimer\u2019s disease. Disease-a-Month. 1985;31:8\u201369. doi: 10.1016/0011-5029(85)90025-2.", "ArticleIdList": ["10.1016/0011-5029(85)90025-2", "3886334"]}, {"Citation": "Terry R.D., Davies P. Dementia of the Alzheimer Type. Annu. Rev. Neurosci. 1980;3:77\u201395. doi: 10.1146/annurev.ne.03.030180.000453.", "ArticleIdList": ["10.1146/annurev.ne.03.030180.000453", "6251745"]}, {"Citation": "Rathmann K.L., Conner C.S. Alzheimer\u2019s disease: Clinical Features, Pathogenesis, and Treatment. Ann. Pharmacother. 2007;41:1499\u20131504. doi: 10.1345/aph.140065.", "ArticleIdList": ["10.1345/aph.140065", "17698893"]}, {"Citation": "Yiannopoulou K.G., Papageorgiou S.G. Current and Future Treatments in Alzheimer\u2019s disease: An Update. J. Cent. Nerv. Syst. Dis. 2020;12:1179573520907397. doi: 10.1177/1179573520907397.", "ArticleIdList": ["10.1177/1179573520907397", "PMC7050025", "32165850"]}, {"Citation": "Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Brayne C., Burns A., Cohen-Mansfield J., Cooper C., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413\u2013446. doi: 10.1016/S0140-6736(20)30367-6.", "ArticleIdList": ["10.1016/S0140-6736(20)30367-6", "PMC7392084", "32738937"]}, {"Citation": "Imtiaz B., Tolppanen A.-M., Kivipelto M., Soininen H. Future directions in Alzheimer\u2019s disease from risk factors to prevention. Biochem. Pharmacol. 2014;88:661\u2013670. doi: 10.1016/j.bcp.2014.01.003.", "ArticleIdList": ["10.1016/j.bcp.2014.01.003", "24418410"]}, {"Citation": "Gonz\u00e1lez-Maciel A., Reynoso-Robles R., Torres-Jard\u00f3n R., Mukherjee P.S., Calder\u00f3n-Garcidue\u00f1as L. Combustion-Derived Nanoparticles in Key Brain Target Cells and Organelles in Young Urbanites: Culprit Hidden in Plain Sight in Alzheimer\u2019s disease Development. J. Alzheimer\u2019s Dis. 2017;59:189\u2013208. doi: 10.3233/JAD-170012.", "ArticleIdList": ["10.3233/JAD-170012", "28598844"]}, {"Citation": "Reitz C., Mayeux R. Alzheimer\u2019s disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014;88:640\u2013651. doi: 10.1016/j.bcp.2013.12.024.", "ArticleIdList": ["10.1016/j.bcp.2013.12.024", "PMC3992261", "24398425"]}, {"Citation": "Tikhonova M.A., Chang H.M., Singh S.K., Vieau D. Experimental and Innovative Approaches to Multi-Target Treatment of Parkinson\u2019s and Alzheimer\u2019s diseases. Front. Neurosci. 2022;16:910020. doi: 10.3389/fnins.2022.910020.", "ArticleIdList": ["10.3389/fnins.2022.910020", "PMC9150500", "35651630"]}, {"Citation": "Rajan K.B., Weuve J., Barnes L.L., Wilson R.S., Evans D.A. Prevalence and incidence of clinically diagnosed Alzheimer\u2019s disease dementia from 1994 to 2012 in a population study. Alzheimer\u2019s Dement. 2018;15:1\u20137. doi: 10.1016/j.jalz.2018.07.216.", "ArticleIdList": ["10.1016/j.jalz.2018.07.216", "PMC6531287", "30195482"]}, {"Citation": "Alzheimer\u2019s Association 2021 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 2021;17:327\u2013406. doi: 10.1002/alz.12328.", "ArticleIdList": ["10.1002/alz.12328", "33756057"]}, {"Citation": "Montgomery W., Ueda K., Jorgensen M., Stathis S., Cheng Y., Nakamura T. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer\u2019s disease in Japan. Clin. Outcomes Res. 2018;10:13\u201328. doi: 10.2147/CEOR.S146788.", "ArticleIdList": ["10.2147/CEOR.S146788", "PMC5749549", "29343976"]}, {"Citation": "Fiest K.M., Roberts J.I., Maxwell C.J., Hogan D., Smith E.E., Frolkis A., Cohen A., Kirk A., Pearson D., Pringsheim T., et al. The Prevalence and Incidence of Dementia Due to Alzheimer\u2019s disease: A Systematic Review and Meta-Analysis. Can. J. Neurol. Sci. 2016;43((Suppl. 1)):S51\u2013S82. doi: 10.1017/cjn.2016.36.", "ArticleIdList": ["10.1017/cjn.2016.36", "27307128"]}, {"Citation": "Niu H., \u00c1lvarez-\u00c1lvarez I., Guill\u00e9n-Grima F., Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer\u2019s disease in Europe: A meta-analysis. Neurologia. 2017;32:523\u2013532. doi: 10.1016/j.nrl.2016.02.016.", "ArticleIdList": ["10.1016/j.nrl.2016.02.016", "27130306"]}, {"Citation": "Takizawa C., Thompson P.L., van Walsem A., Faure C., Maier W.C. Epidemiological and Economic Burden of Alzheimer\u2019s disease: A Systematic Literature Review of Data across Europe and the United States of America. J. Alzheimer\u2019s Dis. 2015;43:1271\u20131284. doi: 10.3233/JAD-141134.", "ArticleIdList": ["10.3233/JAD-141134", "25159675"]}, {"Citation": "Cui L., Hou N.-N., Wu H.-M., Zuo X., Lian Y.-Z., Zhang C.-N., Wang Z.-F., Zhang X., Zhu J.-H. Prevalence of Alzheimer\u2019s disease and Parkinson\u2019s Disease in China: An Updated Systematical Analysis. Front. Aging Neurosci. 2020;12:603854. doi: 10.3389/fnagi.2020.603854.", "ArticleIdList": ["10.3389/fnagi.2020.603854", "PMC7793643", "33424580"]}, {"Citation": "Zhao X., Li X. The prevalence of Alzheimer\u2019s disease in the Chinese Han population: A meta-analysis. Neurol. Res. 2020;42:291\u2013298. doi: 10.1080/01616412.2020.1716467.", "ArticleIdList": ["10.1080/01616412.2020.1716467", "32138626"]}, {"Citation": "Chan K.Y., Wang W., Wu J.J., Liu L., Theodoratou E., Car J., Middleton L., Russ T.C., Deary I.J., Campbell H., et al. Epidemiology of Alzheimer\u2019s disease and other forms of dementia in China, 1990\u20132010: A systematic review and analysis. Lancet. 2013;381:2016\u20132023. doi: 10.1016/S0140-6736(13)60221-4.", "ArticleIdList": ["10.1016/S0140-6736(13)60221-4", "23746902"]}, {"Citation": "GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88\u2013106. doi: 10.1016/S1474-4422(18)30403-4.", "ArticleIdList": ["10.1016/S1474-4422(18)30403-4", "PMC6291454", "30497964"]}, {"Citation": "Niu H., Alvarez-Alvarez I., Guillen-Grima F., Al-Rahamneh M.J., Aguinaga-Ontoso I. Trends of mortality from Alzheimer\u2019s disease in the European Union, 1994\u20132013. Eur. J. Neurol. 2017;24:858\u2013866. doi: 10.1111/ene.13302.", "ArticleIdList": ["10.1111/ene.13302", "28544405"]}, {"Citation": "Park J. Mortality from Alzheimer\u2019s disease in Canada: A multiple-cause-of-death analysis, 2004 to 2011. Health Rep. 2016;27:17\u201321.", "ArticleIdList": ["27192207"]}, {"Citation": "Kramarow E.A., Tejada-Vera B. Dementia Mortality in the United States, 2000\u20132017. Natl. Vital Stat. Rep. Cent. Dis. Control Prev. Natl. Cent. Health Stat. Natl. Vital Stat. Syst. 2019;68:1\u201329.", "ArticleIdList": ["31112120"]}, {"Citation": "Price A., Farooq R., Yuan J.-M., Menon V.B., Cardinal R., O\u2019Brien J. Mortality in dementia with Lewy bodies compared with Alzheimer\u2019s dementia: A retrospective naturalistic cohort study. BMJ Open. 2017;7:e017504. doi: 10.1136/bmjopen-2017-017504.", "ArticleIdList": ["10.1136/bmjopen-2017-017504", "PMC5695389", "29101136"]}, {"Citation": "Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer\u2019s Dement. 2013;9:63\u201375.e2. doi: 10.1016/j.jalz.2012.11.007.", "ArticleIdList": ["10.1016/j.jalz.2012.11.007", "23305823"]}, {"Citation": "Kumar A., Singh A., Ekavali A review on Alzheimer\u2019s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015;67:195\u2013203. doi: 10.1016/j.pharep.2014.09.004.", "ArticleIdList": ["10.1016/j.pharep.2014.09.004", "25712639"]}, {"Citation": "Mishra S., Palanivelu K. The effect of curcumin (turmeric) on Alzheimer\u2019s disease: An overview. Ann. Indian Acad. Neurol. 2008;11:13\u201319. doi: 10.4103/0972-2327.40220.", "ArticleIdList": ["10.4103/0972-2327.40220", "PMC2781139", "19966973"]}, {"Citation": "Kametani F., Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front. Neurosci. 2018;12:25. doi: 10.3389/fnins.2018.00025.", "ArticleIdList": ["10.3389/fnins.2018.00025", "PMC5797629", "29440986"]}, {"Citation": "Liu Z., Zhang A., Sun H., Han Y., Kong L., Wang X. Two decades of new drug discovery and development for Alzheimer\u2019s disease. RSC Adv. 2017;7:6046\u20136058. doi: 10.1039/C6RA26737H.", "ArticleIdList": ["10.1039/C6RA26737H"]}, {"Citation": "Prakash A., Dhaliwal G.K., Kumar P., Majeed A.B.A. Brain biometals and Alzheimer\u2019s disease\u2014Boon or bane? Int. J. Neurosci. 2016;127:99\u2013108. doi: 10.3109/00207454.2016.1174118.", "ArticleIdList": ["10.3109/00207454.2016.1174118", "27044501"]}, {"Citation": "Sultzer D.L., Marder S.R. Older Brains are Different: Brain\u2013Behavior Studies and Their Clinical Utility. Am. J. Geriatr. Psychiatry. 2017;25:11\u201312. doi: 10.1016/j.jagp.2016.10.002.", "ArticleIdList": ["10.1016/j.jagp.2016.10.002", "28231870"]}, {"Citation": "Chase T.N., Farlow M.R., Clarence-Smith K. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer\u2019s disease. Neurotherapeutics. 2017;14:405\u2013416. doi: 10.1007/s13311-016-0511-x.", "ArticleIdList": ["10.1007/s13311-016-0511-x", "PMC5398986", "28138837"]}, {"Citation": "Lane R.M., Kivipelto M., Greig N.H. Acetylcholinesterase and Its Inhibition in Alzheimer\u2019s disease. Clin. Neuropharmacol. 2004;27:141\u2013149. doi: 10.1097/00002826-200405000-00011.", "ArticleIdList": ["10.1097/00002826-200405000-00011", "15190239"]}, {"Citation": "Rees T.M., Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease. Drugs Today. 2003;39:75\u201383. doi: 10.1358/dot.2003.39.1.740206.", "ArticleIdList": ["10.1358/dot.2003.39.1.740206", "12669110"]}, {"Citation": "Alvarez A., Alarc\u00f3n R., Opazo C., Campos E.O., Mu\u00f1oz F.J., Calder\u00f3n F.H., Dajas F., Gentry M.K., Doctor B.P., De Mello F.G., et al. Stable Complexes Involving Acetylcholinesterase and Amyloid-\u03b2 Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer\u2019s Fibrils. J. Neurosci. 1998;18:3213\u20133223. doi: 10.1523/JNEUROSCI.18-09-03213.1998.", "ArticleIdList": ["10.1523/JNEUROSCI.18-09-03213.1998", "PMC6792661", "9547230"]}, {"Citation": "Radic Z., Pickering N.A., Vellom D.C., Camp S., Taylor P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry. 1993;32:12074\u201312084. doi: 10.1021/bi00096a018.", "ArticleIdList": ["10.1021/bi00096a018", "8218285"]}, {"Citation": "Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer\u2019s disease: Clinical trials and drug development. Lancet Neurol. 2010;9:702\u2013716. doi: 10.1016/S1474-4422(10)70119-8.", "ArticleIdList": ["10.1016/S1474-4422(10)70119-8", "20610346"]}, {"Citation": "Vyklicky V., Korinek M., Smejkalova T., Balik A., Krausova B., Kaniakova M., Lichnerova K., \u010cern\u00fd J., Krusek J., Dittert I., et al. Structure, Function, and Pharmacology of NMDA Receptor Channels. Physiol. Res. 2014;63:S191\u2013S203. doi: 10.33549/physiolres.932678.", "ArticleIdList": ["10.33549/physiolres.932678", "24564659"]}, {"Citation": "Foster T., Kyritsopoulos C., Kumar A. Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer\u2019s disease. Behav. Brain Res. 2017;322:223\u2013232. doi: 10.1016/j.bbr.2016.05.012.", "ArticleIdList": ["10.1016/j.bbr.2016.05.012", "27180169"]}, {"Citation": "Ito K., Tatebe T., Suzuki K., Hirayama T., Hayakawa M., Kubo H., Tomita T., Makino M. Memantine reduces the production of amyloid-\u03b2 peptides through modulation of amyloid precursor protein trafficking. Eur. J. Pharmacol. 2017;798:16\u201325. doi: 10.1016/j.ejphar.2017.02.001.", "ArticleIdList": ["10.1016/j.ejphar.2017.02.001", "28167259"]}, {"Citation": "Kumar G., Patnaik R. Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study. Med. Hypotheses. 2016;92:35\u201343. doi: 10.1016/j.mehy.2016.04.034.", "ArticleIdList": ["10.1016/j.mehy.2016.04.034", "27241252"]}, {"Citation": "Kang Q., Xiang Y., Li D., Liang J., Zhang X., Zhou F., Qiao M., Nie Y., He Y., Cheng J., et al. MiR-124-3p attenuates hyperphosphorylation of tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3\u03b2 pathway in N2a/APP695swe cells. Oncotarget. 2017;8:24314\u201324326. doi: 10.18632/oncotarget.15149.", "ArticleIdList": ["10.18632/oncotarget.15149", "PMC5421849", "28186985"]}, {"Citation": "Wang J.-Z., Xia Y.-Y., Grundke-Iqbal I., Iqbal K. Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. J. Alzheimer\u2019s Dis. 2013;33((Suppl. 1)):S123\u2013S139. doi: 10.3233/JAD-2012-129031.", "ArticleIdList": ["10.3233/JAD-2012-129031", "22710920"]}, {"Citation": "Lin C.-H., Hsieh Y.-S., Wu Y.-R., Hsu C.-J., Chen H.-C., Huang W.-H., Chang K.-H., Hsieh-Li H.M., Su M.-T., Sun Y.-C., et al. Identifying GSK-3\u03b2 kinase inhibitors of Alzheimer\u2019s disease: Virtual screening, enzyme, and cell assays. Eur. J. Pharm. Sci. 2016;89:11\u201319. doi: 10.1016/j.ejps.2016.04.012.", "ArticleIdList": ["10.1016/j.ejps.2016.04.012", "27094783"]}, {"Citation": "Coimbra J., Marques D.F.F., Baptista S.J., Pereira C.M.F., Moreira P.I., Dinis T.C.P., Santos A.E., Salvador J.A.R. Highlights in BACE1 Inhibitors for Alzheimer\u2019s disease Treatment. Front. Chem. 2018;6:178. doi: 10.3389/fchem.2018.00178.", "ArticleIdList": ["10.3389/fchem.2018.00178", "PMC5977085", "29881722"]}, {"Citation": "Hampel H., Vassar R., De Strooper B., Hardy J., Willem M., Singh N., Zhou J., Yan R., Vanmechelen E., De Vos A., et al. The \u03b2-Secretase BACE1 in Alzheimer\u2019s disease. Biol. Psychiatry. 2021;89:745\u2013756. doi: 10.1016/j.biopsych.2020.02.001.", "ArticleIdList": ["10.1016/j.biopsych.2020.02.001", "PMC7533042", "32223911"]}, {"Citation": "Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 2014;6:89. doi: 10.1186/s13195-014-0089-7.", "ArticleIdList": ["10.1186/s13195-014-0089-7", "PMC4304279", "25621019"]}, {"Citation": "Suzuki K., Hamada Y., Nguyen J.-T., Kiso Y. Novel BACE1 inhibitors with a non-acidic heterocycle at the P1\u2032 position. Bioorg. Med. Chem. 2013;21:6665\u20136673. doi: 10.1016/j.bmc.2013.08.016.", "ArticleIdList": ["10.1016/j.bmc.2013.08.016", "23993670"]}, {"Citation": "Liu M., Guo H., Li C., Wang D., Wu J., Wang C., Xu J., Qin R.-A. Cognitive improvement of compound danshen in an A\u03b225-35 peptide-induced rat model of Alzheimer\u2019s disease. BMC Complement. Altern. Med. 2015;15:382. doi: 10.1186/s12906-015-0906-y.", "ArticleIdList": ["10.1186/s12906-015-0906-y", "PMC4619010", "26497584"]}, {"Citation": "Kumar M.H.V., Gupta Y.K. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer\u2019s disease in rats. Clin. Exp. Pharmacol. Physiol. 2003;30:336\u2013342. doi: 10.1046/j.1440-1681.2003.03842.x.", "ArticleIdList": ["10.1046/j.1440-1681.2003.03842.x", "12859423"]}, {"Citation": "Begum A.N., Jones M.R., Lim G.P., Morihara T., Kim P., Heath D.D., Rock C.L., Pruitt M.A., Yang F., Hudspeth B., et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer\u2019s disease. J. Pharmacol. Exp. Ther. 2008;326:196\u2013208. doi: 10.1124/jpet.108.137455.", "ArticleIdList": ["10.1124/jpet.108.137455", "PMC2527621", "18417733"]}, {"Citation": "Bihaqi S.W., Sharma M., Singh A.P., Tiwari M. Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. J. Ethnopharmacol. 2009;124:409\u2013415. doi: 10.1016/j.jep.2009.05.038.", "ArticleIdList": ["10.1016/j.jep.2009.05.038", "19505562"]}, {"Citation": "Mokhtarian A., Esfandiari E., Ghanadian M., Rashidi B., Vatankhah A.M. The effects of Acorus calamus L. in preventing memory loss, anxiety, and oxidative stress on lipopolysaccharide-induced neuroinflammation rat models. Int. J. Prev. Med. 2018;9:85. doi: 10.4103/ijpvm.IJPVM_75_18.", "ArticleIdList": ["10.4103/ijpvm.IJPVM_75_18", "PMC6202774", "30450168"]}, {"Citation": "Oh M., Houghton P., Whang W., Cho J. Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine. 2004;11:544\u2013548. doi: 10.1016/j.phymed.2004.03.001.", "ArticleIdList": ["10.1016/j.phymed.2004.03.001", "15500267"]}, {"Citation": "Chauhan N.B., Lahiri D.K. The \u201cAged Garlic Extract\u201d (AGE) and one of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer\u2019s disease (AD) Curr. Med. Chem. 2011;18:3306\u20133313. doi: 10.2174/092986711796504664.", "ArticleIdList": ["10.2174/092986711796504664", "PMC3941700", "21728972"]}, {"Citation": "Chauhan N.B. Anti-Amyloidogenic Effect of Allium sativum in Alzheimer\u2019s Transgenic Model Tg2576. J. Herb. Pharmacother. 2003;3:95\u2013107. doi: 10.1080/J157v03n01_05.", "ArticleIdList": ["10.1080/J157v03n01_05", "15277073"]}, {"Citation": "Mukherjee D., Banerjee S. Learning and memory promoting effects of crude garlic extract. Indian J. Exp. Biol. 2013;51:1094\u20131100.", "ArticleIdList": ["24579375"]}, {"Citation": "Sorrenti V., Contarini G., Sut S., Dall\u2019Acqua S., Confortin F., Pagetta A., Giusti P., Zusso M. Curcumin Prevents Acute Neuroinflammation and Long-Term Memory Impairment Induced by Systemic Lipopolysaccharide in Mice. Front. Pharmacol. 2018;9:183. doi: 10.3389/fphar.2018.00183.", "ArticleIdList": ["10.3389/fphar.2018.00183", "PMC5845393", "29556196"]}, {"Citation": "Budzynska B., Boguszewska-Czubara A., Kruk-Slomka M., Skalicka-Wo\u017aniak K., Michalak A., Musik I., Biala G. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology. 2015;232:931\u2013942. doi: 10.1007/s00213-014-3728-6.", "ArticleIdList": ["10.1007/s00213-014-3728-6", "PMC4325182", "25189792"]}, {"Citation": "Ohba T., Yoshino Y., Ishisaka M., Abe N., Tsuruma K., Shimazawa M., Oyama M., Tabira T., Hara H. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice. Biosci. Biotechnol. Biochem. 2015;79:1838\u20131844. doi: 10.1080/09168451.2015.1052773.", "ArticleIdList": ["10.1080/09168451.2015.1052773", "26059088"]}, {"Citation": "Rubio J., Dang H., Gong M., Liu X., Chen S.-L., Gonzales G.F. Aqueous and hydroalcoholic extracts of Black Maca (Lepidium meyenii) improve scopolamine-induced memory impairment in mice. Food Chem. Toxicol. 2007;45:1882\u20131890. doi: 10.1016/j.fct.2007.04.002.", "ArticleIdList": ["10.1016/j.fct.2007.04.002", "17543435"]}, {"Citation": "Bhattacharya S.K., Bhattacharya A., Kumar A., Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, stria-tum and hippocampus. Phytother. Res. 2000;14:174\u2013179. doi: 10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O.", "ArticleIdList": ["10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O", "10815010"]}, {"Citation": "Chaudhari K.S., Tiwari N.R., Tiwari R.R., Sharma R.S. Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer\u2019s disease. Ann. Neurosci. 2017;24:111\u2013122. doi: 10.1159/000475900.", "ArticleIdList": ["10.1159/000475900", "PMC5448442", "28588366"]}, {"Citation": "Shinomol G.K., Bharath M.M.S. Muralidhara Neuromodulatory Propensity of Bacopa monnieri Leaf Extract Against 3-Nitropropionic Acid-Induced Oxidative Stress: In Vitro and In Vivo Evidences. Neurotox. Res. 2011;22:102\u2013114. doi: 10.1007/s12640-011-9303-6.", "ArticleIdList": ["10.1007/s12640-011-9303-6", "22203611"]}, {"Citation": "Jyoti A., Sharma D. Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain. Neurotoxicology. 2006;27:451\u2013457. doi: 10.1016/j.neuro.2005.12.007.", "ArticleIdList": ["10.1016/j.neuro.2005.12.007", "16500707"]}, {"Citation": "Goswami S., Saoji A., Kumar N., Thawani V., Tiwari M., Thawani M. Effect of Bacopa monnieri on Cognitive functions in Alzheimer\u2019s disease patients. Int. J. Collab. Res. Intern. Med. Public Health. 2011;3:285\u2013293."}, {"Citation": "Yassin Nemat A.Z., El-Shenawy S.M.A., Mahdy K.A., Gouda N.A.M., Marrie A.E.-F.H., Farrag A.R.H., Bassant M.M. Ibrahim. Effect of Boswellia serrata on Alzheimer\u2019s disease induced in rats. J. Arab Soc. Med. Res. 2013;8:1\u201311. doi: 10.7123/01.JASMR.0000429323.25743.cc.", "ArticleIdList": ["10.7123/01.JASMR.0000429323.25743.cc"]}, {"Citation": "Alama B., Haque E. Anti-Alzheimer Antioxidant Activity of Celastrus paniculatus Seed. Iran J. Pharm. Sci. Winter. 2011;7:49\u201356."}, {"Citation": "Saxena G., Singh S.P., Pal R., Singh S., Pratap R., Nath C. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol. Biochem. Behav. 2007;86:797\u2013805. doi: 10.1016/j.pbb.2007.03.010.", "ArticleIdList": ["10.1016/j.pbb.2007.03.010", "17477963"]}, {"Citation": "Nahata A., Patil U.K., Dixit V.K. Effect of Evolvulus alsinoides Linn. on learning behavior and memory enhancement activity in rodents. Phytotherapy Res. 2009;24:486\u2013493. doi: 10.1002/ptr.2932.", "ArticleIdList": ["10.1002/ptr.2932", "19610035"]}, {"Citation": "Joshi H., Parle M. Cholinergic Basis of Memory-Strengthening Effect of Foeniculum vulgare Linn. J. Med. Food. 2006;9:413\u2013417. doi: 10.1089/jmf.2006.9.413.", "ArticleIdList": ["10.1089/jmf.2006.9.413", "17004908"]}, {"Citation": "Hager K., Kenklies M., McAfoose J., Engel J., M\u00fcnch G. \u03b1-Lipoic acid as a new treatment option for Alzheimer\u2019s disease\u2014A 48 months follow-up analysis. J. Neural Transm. Suppl. 2007;72:189\u2013193. doi: 10.1007/978-3-211-73574-9_24.", "ArticleIdList": ["10.1007/978-3-211-73574-9_24", "17982894"]}, {"Citation": "Bickel U., Thomsen T., Fischer J., Weber W., Kewitz H. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology. 1991;30:447\u2013454. doi: 10.1016/0028-3908(91)90005-V.", "ArticleIdList": ["10.1016/0028-3908(91)90005-V", "1865992"]}, {"Citation": "Liu X., Hao W., Qin Y., Decker Y., Wang X., Burkart M., Sch\u00f6tz K., Menger M.D., Fassbender K., Liu Y. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer\u2019s disease. Brain Behav. Immun. 2015;46:121\u2013131. doi: 10.1016/j.bbi.2015.01.011.", "ArticleIdList": ["10.1016/j.bbi.2015.01.011", "25637484"]}, {"Citation": "Cui Y.-M., Ao M.-Z., Li W., Yu L.-J. Effect of Glabridin from Glycyrrhiza glabra on Learning and Memory in Mice. Planta Med. 2008;74:377\u2013380. doi: 10.1055/s-2008-1034319.", "ArticleIdList": ["10.1055/s-2008-1034319", "18484526"]}, {"Citation": "Lee J.W., Lee Y.K., Lee B.J., Nam S.-Y., Lee S.I., Kim Y.H., Kim K.H., Oh K.-W., Hong J.T. Inhibitory effect of ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol. Biochem. Behav. 2010;95:31\u201340. doi: 10.1016/j.pbb.2009.12.003.", "ArticleIdList": ["10.1016/j.pbb.2009.12.003", "20004682"]}, {"Citation": "Soodi M., Naghdi N., Hajimehdipoor H., Choopani S., Sahraei E. Memory-improving activity of Melissa officinalis extract in na\u00efve and scopolamine-treated rats. Res. Pharm. Sci. 2014;9:107\u2013114.", "ArticleIdList": ["PMC4311288", "25657779"]}, {"Citation": "Mahaman Y.A.R., Huang F., Wu M., Wang Y., Wei Z., Bao J., Salissou M.T.M., Ke D., Wang Q., Liu R., et al. Moringa oleifera Alleviates Homocysteine-Induced Alzheimer\u2019s disease-Like Pathology and Cognitive Impairments. J. Alzheimer\u2019s Dis. 2018;63:1141\u20131159. doi: 10.3233/JAD-180091.", "ArticleIdList": ["10.3233/JAD-180091", "PMC6004908", "29710724"]}, {"Citation": "Joshi H., Parle M. Nardostachys jatamansi Improves Learning and Memory in Mice. J. Med. Food. 2006;9:113\u2013118. doi: 10.1089/jmf.2006.9.113.", "ArticleIdList": ["10.1089/jmf.2006.9.113", "16579738"]}, {"Citation": "Kim H.-J., Jung S.-W., Kim S.-Y., Cho I.-H., Kim H.-C., Rhim H., Kim M., Nah S.-Y. Panax ginseng as an adjuvant treatment for Alzheimer\u2019s disease. J. Ginseng Res. 2018;42:401\u2013411. doi: 10.1016/j.jgr.2017.12.008.", "ArticleIdList": ["10.1016/j.jgr.2017.12.008", "PMC6190533", "30337800"]}, {"Citation": "Uddin S., Al Mamun A., Hossain S., Ashaduzzaman M., Noor A.A., Hossain S., Uddin J., Sarker J. Asaduzzaman Neuroprotective Effect of Phyllanthus acidus L. on Learning and Memory Impairment in Scopolamine-Induced Animal Model of Dementia and Oxidative Stress: Natural Wonder for Regulating the Development and Progression of Alzheimer\u2019s disease. Adv. Alzheimer\u2019s Dis. 2016;05:53\u201372. doi: 10.4236/aad.2016.52005.", "ArticleIdList": ["10.4236/aad.2016.52005"]}, {"Citation": "Ozarowski M., Mikolajczak P.L., Bogacz A., Gryszczynska A., Kujawska M., Jodynis-Liebert J., Piasecka A., Napieczynska H., Szulc M., Kujawski R., et al. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia. 2013;91:261\u2013271. doi: 10.1016/j.fitote.2013.09.012.", "ArticleIdList": ["10.1016/j.fitote.2013.09.012", "24080468"]}, {"Citation": "Sallam A., Mira A., Ashour A., Shimizu K. Acetylcholine esterase inhibitors and melanin synthesis inhibitors from Salvia officinalis. Phytomedicine. 2016;23:1005\u20131011. doi: 10.1016/j.phymed.2016.06.014.", "ArticleIdList": ["10.1016/j.phymed.2016.06.014", "27444345"]}, {"Citation": "Misra B.B., Dey S. TLC-Bioautographic Evaluation of In Vitro Anti-tyrosinase and Anti-cholinesterase Potentials of Sandalwood Oil. Nat. Prod. Commun. 2013;8:253\u2013256. doi: 10.1177/1934578X1300800231.", "ArticleIdList": ["10.1177/1934578X1300800231", "23513742"]}, {"Citation": "Agarwal A., Malini S., Bairy K.L., Rao M.S.R. Effect of Tinospora cardifolia on learning and memory in normal and memory deficit rats. Indian J. Pharmacol. 2002;34:339\u2013349."}, {"Citation": "Patel S.S., Gupta S., Udayabanu M. Urtica dioica modulates hippocampal insulin signaling and recognition memory deficit in streptozotocin induced diabetic mice. Metab. Brain Dis. 2016;31:601\u2013611. doi: 10.1007/s11011-016-9791-4.", "ArticleIdList": ["10.1007/s11011-016-9791-4", "26767366"]}, {"Citation": "Bhattacharya S.K., Kumar A., Ghosal S. Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer\u2019s disease and perturbed central cholinergic markers of cognition in rats. Phytotherapy Res. 1995;9:110\u2013113. doi: 10.1002/ptr.2650090206.", "ArticleIdList": ["10.1002/ptr.2650090206"]}, {"Citation": "Mathew M., Subramaniam S. In vitro evaluation of anti-Alzheimer effects of dry ginger (Zingiber officinale Roscoe) extract. Indian J. Exp. Biol. 2014;52:606\u2013612.", "ArticleIdList": ["24956891"]}, {"Citation": "Acqua S.D. Plant-derived acetylcholinesterase inhibitory alkaloids for the treatment of Alzheimer\u2019s disease. Bot. Targets Ther. 2013;3:19\u201328. doi: 10.2147/BTAT.S17297.", "ArticleIdList": ["10.2147/BTAT.S17297"]}, {"Citation": "Razay G., Wilcock G.K. Galantamine in Alzheimer\u2019s disease. Expert Rev. Neurother. 2008;8:9\u201317. doi: 10.1586/14737175.8.1.9.", "ArticleIdList": ["10.1586/14737175.8.1.9", "18088197"]}, {"Citation": "Maelicke A., Hoeffle-Maas A., Ludwig J., Maus A., Samochocki M., Jordis U., Koepke A.K.E. Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy. J. Mol. Neurosci. 2009;40:135\u2013137. doi: 10.1007/s12031-009-9269-5.", "ArticleIdList": ["10.1007/s12031-009-9269-5", "19669943"]}, {"Citation": "Nillert N., Pannangrong W., Welbat J.U., Chaijaroonkhanarak W., Sripanidkulchai K., Sripanidkulchai B. Neuroprotective Effects of Aged Garlic Extract on Cognitive Dysfunction and Neuroinflammation Induced by \u03b2-Amyloid in Rats. Nutrients. 2017;9:24. doi: 10.3390/nu9010024.", "ArticleIdList": ["10.3390/nu9010024", "PMC5295068", "28054940"]}, {"Citation": "Rebai O., Belkhir M., Sanchez-Gomez M.V., Matute C., Fattouch S., Amri M. Differential Molecular Targets for Neuroprotective Effect of Chlorogenic Acid and its Related Compounds Against Glutamate Induced Excitotoxicity and Oxidative Stress in Rat Cortical Neurons. Neurochem. Res. 2017;42:3559\u20133572. doi: 10.1007/s11064-017-2403-9.", "ArticleIdList": ["10.1007/s11064-017-2403-9", "28948515"]}, {"Citation": "Ali Y.O., Bradley G., Lu H.-C. Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons. Sci. Rep. 2017;7:43846. doi: 10.1038/srep43846.", "ArticleIdList": ["10.1038/srep43846", "PMC5358788", "28266613"]}, {"Citation": "Thaipisuttikul P., Galvin J.E. Use of medical foods and nutritional approaches in the treatment of Alzheimer\u2019s disease. Clin. Pract. 2012;9:199\u2013209. doi: 10.2217/cpr.12.3.", "ArticleIdList": ["10.2217/cpr.12.3", "PMC3556480", "23362453"]}, {"Citation": "Frydman-Marom A., Levin A., Farfara R., Benromano T., Scherzer-Attali R., Peled S., Vassar R., Segal D., Gazit E., Frenkel D., et al. Orally Administrated Cinnamon Extract Reduces \u03b2-Amyloid Oligomerization and Corrects Cognitive Impairment in Alzheimer\u2019s disease Animal Models. PLoS ONE. 2011;6:e16564. doi: 10.1371/journal.pone.0016564.", "ArticleIdList": ["10.1371/journal.pone.0016564", "PMC3030596", "21305046"]}, {"Citation": "Rajakrishnan V., Viswanathan P., Rajasekharan K.N., Menon V.P. Neuroprotective role of curcumin from Curcuma longa on ethanol-induced brain damage. Phytother. Res. 1999;13:571\u2013574. doi: 10.1002/(SICI)1099-1573(199911)13:7<571::AID-PTR494>3.0.CO;2-7.", "ArticleIdList": ["10.1002/(SICI)1099-1573(199911)13:7<571::AID-PTR494>3.0.CO;2-7", "10548748"]}, {"Citation": "Yavarpour-Bali H., Ghasemi-Kasman M., Pirzadeh M. Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomed. 2019;14:4449\u20134460. doi: 10.2147/IJN.S208332.", "ArticleIdList": ["10.2147/IJN.S208332", "PMC6592058", "31417253"]}, {"Citation": "Cole G.M., Ma Q.-L., Frautschy S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot. Essent. Fat. Acids. 2009;81:213\u2013221. doi: 10.1016/j.plefa.2009.05.015.", "ArticleIdList": ["10.1016/j.plefa.2009.05.015", "PMC4019002", "19523795"]}, {"Citation": "Wang Y.-J., Thomas P., Zhong J.-H., Bi F.-F., Kosaraju S., Pollard A., Fenech M., Zhou X.-F. Consumption of Grape Seed Extract Prevents Amyloid-\u03b2 Deposition and Attenuates Inflammation in Brain of an Alzheimer\u2019s disease Mouse. Neurotox. Res. 2009;15:3\u201314. doi: 10.1007/s12640-009-9000-x.", "ArticleIdList": ["10.1007/s12640-009-9000-x", "19384583"]}, {"Citation": "Li S., Wang C., Wang M., Li W., Matsumoto K., Tang Y. Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci. 2007;80:1373\u20131381. doi: 10.1016/j.lfs.2006.12.027.", "ArticleIdList": ["10.1016/j.lfs.2006.12.027", "17289085"]}, {"Citation": "Williams P., Sorribas A., Howes M.-J.R. Natural products as a source of Alzheimer\u2019s drug leads. Nat. Prod. Rep. 2010;28:48\u201377. doi: 10.1039/C0NP00027B.", "ArticleIdList": ["10.1039/C0NP00027B", "PMC4917364", "21072430"]}, {"Citation": "Liu B., Liu J., Shi J.S. SAMP8 Mice as a Model of Age-Related Cognition Decline with Underlying Mechanisms in Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 2020;75:385\u2013395. doi: 10.3233/JAD-200063.", "ArticleIdList": ["10.3233/JAD-200063", "32310176"]}, {"Citation": "Moreno L.C.G.E.I., Puerta E., Su\u00e1rez-Santiago J.E., Santos-Magalh\u00e3es N.S., Ramirez M.J., Irache J.M. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer\u2019s disease. Int. J. Pharm. 2017;517:50\u201357. doi: 10.1016/j.ijpharm.2016.11.061.", "ArticleIdList": ["10.1016/j.ijpharm.2016.11.061", "27915007"]}, {"Citation": "de Andrade Teles R.B., Diniz T.C., Costa Pinto T.C., de Oliveira Junior R.G., Gama E.S.M., de Lavor E.M., Fernandes A.W.C., de Oliveira A.P., de Almeida Ribeiro F.P.R., da Silva A.A.M., et al. Flavonoids as Therapeutic Agents in Alzheimer\u2019s and Parkinson\u2019s Diseases: A Systematic Review of Preclinical Evidences. Oxid. Med. Cell. Longev. 2018;2018:7043213. doi: 10.1155/2018/7043213.", "ArticleIdList": ["10.1155/2018/7043213", "PMC5971291", "29861833"]}, {"Citation": "Kumar A., Nisha C.M., Silakari C., Sharma I., Anusha K., Gupta N., Nair P., Tripathi T., Kumar A. Current and novel therapeutic molecules and targets in Alzheimer\u2019s disease. J. Formos. Med. Assoc. 2016;115:3\u201310. doi: 10.1016/j.jfma.2015.04.001.", "ArticleIdList": ["10.1016/j.jfma.2015.04.001", "26220908"]}, {"Citation": "Nelson L., Tabet N. Slowing the progression of Alzheimer\u2019s disease; what works? Ageing Res. Rev. 2015;23:193\u2013209. doi: 10.1016/j.arr.2015.07.002.", "ArticleIdList": ["10.1016/j.arr.2015.07.002", "26219494"]}, {"Citation": "Hampel H., Mesulam M.M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u20131933. doi: 10.1093/brain/awy132.", "ArticleIdList": ["10.1093/brain/awy132", "PMC6022632", "29850777"]}, {"Citation": "Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer\u2019s disease. Drugs Aging. 2001;8:853\u2013862. doi: 10.2165/00002512-200118110-00006.", "ArticleIdList": ["10.2165/00002512-200118110-00006", "11772125"]}, {"Citation": "Crismon M.L. Tacrine: First Drug Approved for Alzheimer\u2019s disease. Ann. Pharmacother. 1994;28:744\u2013751. doi: 10.1177/106002809402800612.", "ArticleIdList": ["10.1177/106002809402800612", "7919566"]}, {"Citation": "Qizilbash N., Birks J., Arrieta J.L., Lewington S., Szeto S. Tacrine for Alzheimer\u2019s disease. Cochrane Database Syst. Rev. 2000;2:CD000202. doi: 10.1002/14651858.cd000202.", "ArticleIdList": ["10.1002/14651858.cd000202", "10796507"]}, {"Citation": "Ferreira-Vieira T.H., Guimaraes I.M., Silva F.R., Ribeiro F.M. Alzheimer\u2019s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 2016;14:101\u2013115. doi: 10.2174/1570159X13666150716165726.", "ArticleIdList": ["10.2174/1570159X13666150716165726", "PMC4787279", "26813123"]}, {"Citation": "Kabir T., Uddin S., Begum M.M., Thangapandiyan S., Rahman S., Aleya L., Mathew B., Ahmed M., Barreto G.E., Ashraf G. Cholinesterase Inhibitors for Alzheimer\u2019s disease: Multitargeting Strategy Based on Anti-Alzheimer\u2019s Drugs Repositioning. Curr. Pharm. Des. 2019;25:3519\u20133535. doi: 10.2174/1381612825666191008103141.", "ArticleIdList": ["10.2174/1381612825666191008103141", "31593530"]}, {"Citation": "Cacabelos R. Donepezil in Alzheimer\u2019s disease: From conventional trials to pharmacogenetics. Neuropsychiatr. Dis. Treat. 2007;3:303\u2013333.", "ArticleIdList": ["PMC2654795", "19300564"]}, {"Citation": "Kumar A., Sharma S.  StatPearl. StatPearls Publishing; Treasure Island, FL, USA: 2020.  [(accessed on 8 December 2020)]. Donepezil. Available online:  https://www.ncbi.nlm.nih.gov/books/NBK513257/"}, {"Citation": "Dooley M., Lamb H.M. Donepezil: A review of its use in Alzheimer\u2019s disease. Drugs Aging. 2000;16:199\u2013226. doi: 10.2165/00002512-200016030-00005.", "ArticleIdList": ["10.2165/00002512-200016030-00005", "10803860"]}, {"Citation": "Grossberg G.T. Cholinesterase Inhibitors for the Treatment of Alzheimer\u2019s disease: Getting On and Staying On. Curr. Ther. Res. 2003;64:216\u2013235. doi: 10.1016/S0011-393X(03)00059-6.", "ArticleIdList": ["10.1016/S0011-393X(03)00059-6", "PMC4052996", "24944370"]}, {"Citation": "Annicchiarico R., Federici A., Pettenati C., Caltagirone C. Rivastigmine in Alzheimer\u2019s disease: Cognitive function and quali-ty of life. Ther. Clin. Risk Manag. 2007;3:1113\u20131123.", "ArticleIdList": ["PMC2387294", "18516265"]}, {"Citation": "M\u00fcller T. Rivastigmine in the treatment of patients with Alzheimer\u2019s disease. Neuropsychiatr. Dis. Treat. 2007;3:211\u2013218. doi: 10.2147/nedt.2007.3.2.211.", "ArticleIdList": ["10.2147/nedt.2007.3.2.211", "PMC2654625", "19300554"]}, {"Citation": "Khoury R., Rajamanickam J., Grossberg G.T. An update on the safety of current therapies for Alzheimer\u2019s disease: Focus on rivastigmine. Ther. Adv. Drug Saf. 2018;9:171\u2013178. doi: 10.1177/2042098617750555.", "ArticleIdList": ["10.1177/2042098617750555", "PMC5810854", "29492246"]}, {"Citation": "Birks J., Evans J.G., Iakovidou V., Tsolaki M. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst. 2009;4:CD001191. doi: 10.1002/14651858.cd001191.pub2.", "ArticleIdList": ["10.1002/14651858.cd001191.pub2", "19370562"]}, {"Citation": "Scott L.J., Goa K.L. Galantamine. Drugs. 2000;60:1095\u20131122. doi: 10.2165/00003495-200060050-00008.", "ArticleIdList": ["10.2165/00003495-200060050-00008", "11129124"]}, {"Citation": "Prvulovic D., Hampel H., Pantel J. Galantamine for Alzheimer\u2019s disease. Expert Opin. Drug Metab. Toxicol. 2010;6:345\u2013354. doi: 10.1517/17425251003592137.", "ArticleIdList": ["10.1517/17425251003592137", "20113148"]}, {"Citation": "Kim J.K., Park S.U. Pharmacological aspects of galantamine for the treatment of Alzheimer\u2019s disease. EXCLI J. 2017;16:35\u201339. doi: 10.17179/excli2016-820.", "ArticleIdList": ["10.17179/excli2016-820", "PMC5318685", "28337117"]}, {"Citation": "Wahba S.M., Darwish A.S., Kamal S.M. Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer\u2019s disease in ovariectomized albino-rat model. Mater. Sci. Eng. C. 2016;65:151\u2013163. doi: 10.1016/j.msec.2016.04.041.", "ArticleIdList": ["10.1016/j.msec.2016.04.041", "27157738"]}, {"Citation": "Liu J., Chang L., Song Y., Li H., Wu Y. The Role of NMDA Receptors in Alzheimer\u2019s disease. Front. Neurosci. 2019;13:43. doi: 10.3389/fnins.2019.00043.", "ArticleIdList": ["10.3389/fnins.2019.00043", "PMC6375899", "30800052"]}, {"Citation": "Huang Y.-J., Lin C.-H., Lane H.-Y., Tsai G.E. NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer\u2019s disease. Curr. Neuropharmacol. 2012;10:272\u2013285. doi: 10.2174/157015912803217288.", "ArticleIdList": ["10.2174/157015912803217288", "PMC3468881", "23450042"]}, {"Citation": "Companys-Alemany J., Turcu A.L., Bellver-Sanchis A., Loza M.I., Brea J.M., Canudas A.M., Leiva R., V\u00e1zquez S., Pall\u00e0s M., Gri\u00f1\u00e1n-Ferr\u00e9 C. A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice. Pharmaceutics. 2020;12:284. doi: 10.3390/pharmaceutics12030284.", "ArticleIdList": ["10.3390/pharmaceutics12030284", "PMC7151078", "32235699"]}, {"Citation": "Folch J., Busquets O., Ettcheto M., S\u00e1nchez-L\u00f3pez E., Castro-Torres R.D., Verdaguer E., Garcia M.L., Olloquequi J., Casades\u00fas G., Beas-Zarate C., et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J. Alzheimer\u2019s Dis. 2018;62:1223\u20131240. doi: 10.3233/JAD-170672.", "ArticleIdList": ["10.3233/JAD-170672", "PMC5870028", "29254093"]}, {"Citation": "Khan N.H., Mir M., Ngowi E.E., Zafar U., Khakwani M.M.A.K., Khattak S., Zhai Y.-K., Jiang E.-S., Zheng M., Duan S.-F., et al. Nanomedicine: A Promising Way to Manage Alzheimer\u2019s disease. Front. Bioeng. Biotechnol. 2021;9:630055. doi: 10.3389/fbioe.2021.630055.", "ArticleIdList": ["10.3389/fbioe.2021.630055", "PMC8120897", "33996777"]}, {"Citation": "Nguyen T.T., Nguyen T.T.D., Vo T.K., Tran N.-M., Nguyen M.K., Van Vo T., Van Vo G. Nanotechnology-based drug delivery for central nervous system disorders. Biomed. Pharmacother. 2021;143:112117. doi: 10.1016/j.biopha.2021.112117.", "ArticleIdList": ["10.1016/j.biopha.2021.112117", "34479020"]}, {"Citation": "Carradori D., Balducci C., Re F., Brambilla D., Le Droumaguet B., Flores O., Gaudin A., Mura S., Forloni G., Ordo\u00f1ez-Gutierrez L., et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model. Nanomed. Nanotechnol. Biol. Med. 2018;14:609\u2013618. doi: 10.1016/j.nano.2017.12.006.", "ArticleIdList": ["10.1016/j.nano.2017.12.006", "29248676"]}, {"Citation": "S\u00e1nchez-L\u00f3pez E., Ettcheto M., Egea M.A., Espina M., Cano A., Calpena A.C. Memantine loaded PLGA PEGylated nanoparti-cles for Alzheimer\u2019s disease: In vitro and in vivo characterization. J. Nanobiotechnol. 2018;16:32. doi: 10.1186/s12951-018-0356-z.", "ArticleIdList": ["10.1186/s12951-018-0356-z", "PMC5870370", "29587747"]}, {"Citation": "Jeon S.G., Cha M.-Y., Kim J.-I., Hwang T.W., Kim K.A., Kim T.H., Song K.C., Kim J.-J., Moon M. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer\u2019s disease-related pathology in 5XFAD mice. Nanomed. Nanotechnol. Biol. Med. 2019;17:297\u2013307. doi: 10.1016/j.nano.2019.02.004.", "ArticleIdList": ["10.1016/j.nano.2019.02.004", "30794963"]}, {"Citation": "Vilella A., Belletti D., Sauer A.K., Hagmeyer S., Sarowar T., Masoni M., Stasiak N., Mulvihill J.J., Ruozi B., Forni F., et al. Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer\u2019s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J. Trace Elements Med. Biol. 2018;49:210\u2013221. doi: 10.1016/j.jtemb.2017.12.006.", "ArticleIdList": ["10.1016/j.jtemb.2017.12.006", "29325805"]}, {"Citation": "Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 2008;60:1650\u20131662. doi: 10.1016/j.addr.2008.09.001.", "ArticleIdList": ["10.1016/j.addr.2008.09.001", "18848591"]}, {"Citation": "Wilson B., Alobaid B.N.M., Geetha K.M., Jenita J.L. Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer\u2019s disease. J. Drug Deliv. Sci. Technol. 2020;61:102176. doi: 10.1016/j.jddst.2020.102176.", "ArticleIdList": ["10.1016/j.jddst.2020.102176"]}, {"Citation": "Meng Q., Wang A., Hua H., Jiang Y., Wang Y., Mu H., Wu Z., Sun K. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int. J. Nanomed. 2018;13:705\u2013718. doi: 10.2147/IJN.S151474.", "ArticleIdList": ["10.2147/IJN.S151474", "PMC5798568", "29440896"]}, {"Citation": "Elnaggar Y.S., Etman S.M., Abdelmonsif D.A., Abdallah O.Y. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer\u2019s disease: Optimization, Biological Efficacy, and Potential Toxicity. J. Pharm. Sci. 2015;104:3544\u20133556. doi: 10.1002/jps.24557.", "ArticleIdList": ["10.1002/jps.24557", "28739042"]}, {"Citation": "Park S.-Y., Kim H.-S., Cho E.-K., Kwon B.-Y., Phark S., Hwang K.-W., Sul D. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol. 2008;46:2881\u20132887. doi: 10.1016/j.fct.2008.05.030.", "ArticleIdList": ["10.1016/j.fct.2008.05.030", "18573304"]}, {"Citation": "Joseph A., Wood T., Chen C.C., Corry K., Snyder J.M., Juul S.E. Curcumin-loaded polymeric nanoparticles for neuroprotection in neonatal rats with hypoxic-ischemic encephalopathy. Nano Res. 2018;11:5670\u20135688. doi: 10.1007/s12274-018-2104-y.", "ArticleIdList": ["10.1007/s12274-018-2104-y"]}, {"Citation": "Zhang L., Yang S., Wong L.R., Xie H., Ho P.C.-L. In Vitro and In Vivo Comparison of Curcumin-Encapsulated Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles and Curcumin/Hydroxypropyl-\u03b2-Cyclodextrin Inclusion Complexes Administered Intranasally as Therapeutic Strategies for Alzheimer\u2019s disease. Mol. Pharm. 2020;17:4256\u20134269. doi: 10.1021/acs.molpharmaceut.0c00675.", "ArticleIdList": ["10.1021/acs.molpharmaceut.0c00675", "33084343"]}, {"Citation": "Muthukumaran K., Kanwar A., Vegh C., Marginean A., Elliott A., Guilbeault N. Ubisol-Q 10 (a nanomicellar water-soluble formulation of CoQ 10) treatment inhibits Alzheimer-type behavioral and pathological symptoms in a double transgenic mouse (TgAPEswe, PSEN1dE9) model of Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 2018;61:221\u2013236. doi: 10.3233/JAD-170275.", "ArticleIdList": ["10.3233/JAD-170275", "29154270"]}, {"Citation": "Hagl S., Kocher A., Schiborr C., Kolesova N., Frank J., Eckert G.P. Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice\u2014Impact on bioavailability. Neurochem. Int. 2015;89:234\u2013242. doi: 10.1016/j.neuint.2015.07.026.", "ArticleIdList": ["10.1016/j.neuint.2015.07.026", "26254982"]}, {"Citation": "Mirzaie Z., Ansari M., Kordestani S.S., Rezaei M.H., Mozafari M. Preparation and characterization of curcumin-loaded polymeric nanomicelles to interference with amyloidogenesis through glycation method. Biotechnol. Appl. Biochem. 2017;66:537\u2013544. doi: 10.1002/bab.1751.", "ArticleIdList": ["10.1002/bab.1751", "30993734"]}, {"Citation": "Wong K.H., Riaz M.K., Xie Y., Zhang X., Liu Q., Chen H., Bian Z., Chen X., Lu A., Yang Z. Review of Current Strategies for Delivering Alzheimer\u2019s disease Drugs across the Blood-Brain Barrier. Int. J. Mol. Sci. 2019;20:381. doi: 10.3390/ijms20020381.", "ArticleIdList": ["10.3390/ijms20020381", "PMC6358942", "30658419"]}, {"Citation": "Aliev G., Ashraf G.M., Tarasov V.V., Chubarev V.N., Leszek J., Gasiorowski K., Makhmutova A., Baeesa S.S., Avila-Rodr\u00edguez M., Ustyugov A.A., et al. Alzheimer\u2019s disease\u2014Future Therapy Based on Dendrimers. Curr. Neuropharmacol. 2019;17:288\u2013294. doi: 10.2174/1570159X16666180918164623.", "ArticleIdList": ["10.2174/1570159X16666180918164623", "PMC6425077", "30227819"]}, {"Citation": "Gothwal A., Kumar H., Nakhate K.T., Ajazuddin Dutta A., Borah A. Lactoferrin coupled lower generation PAMAM den-drimers for brain targeted delivery of memantine in aluminum-chloride-induced Alzheimer\u2019s disease in mice. Bioconjug. Chem. 2019;30:2573\u20132583. doi: 10.1021/acs.bioconjchem.9b00505.", "ArticleIdList": ["10.1021/acs.bioconjchem.9b00505", "31553175"]}, {"Citation": "Aso E., Martinsson I., Appelhans D., Effenberg C., Benseny Cases N., Cladera J. Poly (propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomed. Nanotechnol. Biol. Med. 2019;17:198\u2013209. doi: 10.1016/j.nano.2019.01.010.", "ArticleIdList": ["10.1016/j.nano.2019.01.010", "30708052"]}, {"Citation": "Seraf\u00edn V., Razzino C.A., Gamella M., Pedrero M., Povedano E., Montero-Calle A., Barderas R., Calero M., Lobo A.O., Y\u00e1\u00f1ez-Sede\u00f1o P., et al. Disposable immunoplatforms for the simultaneous determination of biomarkers for neurodegenerative disorders using poly(amidoamine) dendrimer/gold nanoparticle nanocomposite. Anal. Bioanal. Chem. 2020;413:799\u2013811. doi: 10.1007/s00216-020-02724-3.", "ArticleIdList": ["10.1007/s00216-020-02724-3", "32474723"]}, {"Citation": "Aderibigbe B.A., Naki T. Design and Efficacy of Nanogels Formulations for Intranasal Administration. Molecules. 2018;23:1241. doi: 10.3390/molecules23061241.", "ArticleIdList": ["10.3390/molecules23061241", "PMC6100477", "29789506"]}, {"Citation": "Picone P., Sabatino M.A., Ditta L.A., Amato A., Biagio P.L.S., Mul\u00e8 F., Giacomazza D., Dispenza C., Di Carlo M. Nose-to-brain delivery of insulin enhanced by a nanogel carrier. J. Control. Release. 2018;270:23\u201336. doi: 10.1016/j.jconrel.2017.11.040.", "ArticleIdList": ["10.1016/j.jconrel.2017.11.040", "29196041"]}, {"Citation": "Anani T., Rahmati S., Sultana N., David A.E. MRI-traceable theranostic nanoparticles for targeted cancer treatment. Theranostics. 2021;11:579\u2013601. doi: 10.7150/thno.48811.", "ArticleIdList": ["10.7150/thno.48811", "PMC7738852", "33391494"]}, {"Citation": "Rakotoarisoa M., Angelova A. Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders. Medicines. 2018;5:126. doi: 10.3390/medicines5040126.", "ArticleIdList": ["10.3390/medicines5040126", "PMC6313553", "30477087"]}, {"Citation": "Arduino I., Iacobazzi R.M., Riganti C., Lopedota A.A., Perrone M.G., Lopalco A., Cutrignelli A., Cantore M., Laquintana V., Franco M., et al. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer\u2019s disease. Int. J. Pharm. 2020;591:120011. doi: 10.1016/j.ijpharm.2020.120011.", "ArticleIdList": ["10.1016/j.ijpharm.2020.120011", "33115695"]}, {"Citation": "Serafini M.M., Catanzaro M., Rosini M., Racchi M., Lanni C. Curcumin in Alzheimer\u2019s disease: Can we think to new strategies and perspectives for this molecule? Pharmacol. Res. 2017;124:146\u2013155. doi: 10.1016/j.phrs.2017.08.004.", "ArticleIdList": ["10.1016/j.phrs.2017.08.004", "28811228"]}, {"Citation": "Malvajerd S.S., Izadi Z., Azadi A., Kurd M., Derakhshankhah H., Zadeh M.S., Javar H.A., Hamidi M. Neuroprotective Potential of Curcumin-Loaded Nanostructured Lipid Carrier in an Animal Model of Alzheimer\u2019s disease: Behavioral and Biochemical Evidence. J. Alzheimer\u2019s Dis. 2019;69:671\u2013686. doi: 10.3233/JAD-190083.", "ArticleIdList": ["10.3233/JAD-190083", "31156160"]}, {"Citation": "Rocha S. Targeted drug delivery across the blood brain barrier in Alzheimer\u2019s disease. Curr. Pharm. Des. 2013;19:6635\u20136646. doi: 10.2174/13816128113199990613.", "ArticleIdList": ["10.2174/13816128113199990613", "23621533"]}, {"Citation": "Arora S., Layek B., Singh J. Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood\u2013Brain Barrier for Effective Treatment of Alzheimer\u2019s disease. Mol. Pharm. 2020;18:714\u2013725. doi: 10.1021/acs.molpharmaceut.0c00461.", "ArticleIdList": ["10.1021/acs.molpharmaceut.0c00461", "32787268"]}, {"Citation": "Saraswathi T.S., Mothilal M. Development of rivastigmine loaded self-assembled nanostructures of nonionic surfactants for brain delivery. Int. J. Appl. Pharm. 2021;13:205\u2013215. doi: 10.22159/ijap.2021v13i5.42664.", "ArticleIdList": ["10.22159/ijap.2021v13i5.42664"]}, {"Citation": "Ansari M., Eslami H. Preparation and study of the inhibitory effect of nano-niosomes containing essential oil from artemisia absinthium on amyloid fibril formation. Nanomed. J. 2020;7:243\u2013250. doi: 10.22038/NMJ.2020.07.0009.", "ArticleIdList": ["10.22038/NMJ.2020.07.0009"]}, {"Citation": "Kulkarni P., Rawtani D., Barot T. Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease. Eur. J. Pharm. Biopharm. 2021;163:1\u201315. doi: 10.1016/j.ejpb.2021.02.015.", "ArticleIdList": ["10.1016/j.ejpb.2021.02.015", "33774160"]}, {"Citation": "Kaur A., Nigam K., Srivastava S., Tyagi A., Dang S. Memantine nanoemulsion: A new approach to treat Alzheimer\u2019s disease. J. Microencapsul. 2020;37:355\u2013365. doi: 10.1080/02652048.2020.1756971.", "ArticleIdList": ["10.1080/02652048.2020.1756971", "32293915"]}, {"Citation": "Patil R.P., Pawara D.D., Gudewar C.S., Tekade A.R. Nanostructured cubosomes in an in situ nasal gel system: An alternative approach for the controlled delivery of donepezil HCl to brain. J. Liposome Res. 2018;29:264\u2013273. doi: 10.1080/08982104.2018.1552703.", "ArticleIdList": ["10.1080/08982104.2018.1552703", "30501444"]}, {"Citation": "Sintov A.C. AmyloLipid Nanovesicles: A self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain delivery of curcumin. Int. J. Pharm. 2020;588:119725. doi: 10.1016/j.ijpharm.2020.119725.", "ArticleIdList": ["10.1016/j.ijpharm.2020.119725", "32763387"]}, {"Citation": "Fernandes A.P., Gandin V. Selenium compounds as therapeutic agents in cancer. Biochim. Biophys. Acta (BBA)-Gen. Subj. 2015;1850:1642\u20131660. doi: 10.1016/j.bbagen.2014.10.008.", "ArticleIdList": ["10.1016/j.bbagen.2014.10.008", "25459512"]}, {"Citation": "Huo X., Zhang Y., Jin X., Li Y., Zhang L. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid \u03b2 aggregation in Alzheimer\u2019s disease. J. Photochem. Photobiol. B Biol. 2019;190:98\u2013102. doi: 10.1016/j.jphotobiol.2018.11.008.", "ArticleIdList": ["10.1016/j.jphotobiol.2018.11.008", "30504054"]}, {"Citation": "Rzigalinski B.A., Carfagna C.S., Ehrich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017;9:e1444. doi: 10.1002/wnan.1444.", "ArticleIdList": ["10.1002/wnan.1444", "PMC5422143", "27860449"]}, {"Citation": "Kwon H.J., Cha M.-Y., Kim D., Kim D.K., Soh M., Shin K., Hyeon T., Mook-Jung I. Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer\u2019s disease. ACS Nano. 2016;10:2860\u20132870. doi: 10.1021/acsnano.5b08045.", "ArticleIdList": ["10.1021/acsnano.5b08045", "26844592"]}, {"Citation": "Sivanesan S., Rajeshkumar S. Gold nanoparticles in diagnosis and treatment of Alzheimer\u2019s disease. In: Mahendra R., Alka Y., editors. Nanobiotechnology in Neurodegenerative Diseases. Springer; Cham, Switzerland: 2019. pp. 289\u2013306.", "ArticleIdList": ["10.1007/978-3-030-30930-5_12"]}, {"Citation": "Sanati M., Khodagholi F., Aminyavari S., Ghasemi F., Gholami M., Kebriaeezadeh A. Impact of gold nanoparticles on amyloid \u03b2-induced Alzheimer\u2019s disease in a rat animal model: Involvement of STIM Proteins. ACS Chem. Neurosci. 2019;10:2299\u20132309. doi: 10.1021/acschemneuro.8b00622.", "ArticleIdList": ["10.1021/acschemneuro.8b00622", "30933476"]}, {"Citation": "Dos Santos Tramontin N., da Silva S., Arruda R., Ugioni K.S., Canteiro P.B., de Bem Silveira G. Gold nanoparticles treatment reverses brain damage in Alzheimer\u2019s disease model. Mol. Neurobiol. 2020;57:926\u2013936. doi: 10.1007/s12035-019-01780-w.", "ArticleIdList": ["10.1007/s12035-019-01780-w", "31612296"]}, {"Citation": "Cai J., Dao P., Chen H., Yan L., Li Y.L., Zhang W., Li L., Du Z., Dong C.-Z., Meunier B. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer\u2019s disease. Dyes Pigment. 2020;173:107968. doi: 10.1016/j.dyepig.2019.107968.", "ArticleIdList": ["10.1016/j.dyepig.2019.107968"]}, {"Citation": "Luo S., Ma C., Zhu M.-Q., Ju W.-N., Yang Y., Wang X. Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases with Emphasis on Alzheimer\u2019s disease. Front. Cell. Neurosci. 2020;14:21. doi: 10.3389/fncel.2020.00021.", "ArticleIdList": ["10.3389/fncel.2020.00021", "PMC7058693", "32184709"]}, {"Citation": "Cui Z., Lockman P., Atwood C.S., Hsu C.-H., Gupte A., Allen D.D., Mumper R.J. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases. Eur. J. Pharm. Biopharm. 2005;59:263\u2013272. doi: 10.1016/j.ejpb.2004.07.009.", "ArticleIdList": ["10.1016/j.ejpb.2004.07.009", "15661498"]}, {"Citation": "Liu G., Men P., Kudo W., Perry G., Smith M.A. Nanoparticle\u2013chelator conjugates as inhibitors of amyloid-\u03b2 aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer\u2019s disease. Neurosci. Lett. 2009;455:187\u2013190. doi: 10.1016/j.neulet.2009.03.064.", "ArticleIdList": ["10.1016/j.neulet.2009.03.064", "PMC2683427", "19429118"]}, {"Citation": "Liu G., Men P., Harris P.L., Rolston R.K., Perry G., Smith M.A. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer\u2019s disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 2006;406:189\u2013193. doi: 10.1016/j.neulet.2006.07.020.", "ArticleIdList": ["10.1016/j.neulet.2006.07.020", "16919875"]}, {"Citation": "Williams S.R., Lepene B.S., Thatcher C.D., Long T.E. Synthesis and Characterization of Poly(ethylene glycol)\u2212Glutathione Conjugate Self-Assembled Nanoparticles for Antioxidant Delivery. Biomacromolecules. 2008;10:155\u2013161. doi: 10.1021/bm801058j.", "ArticleIdList": ["10.1021/bm801058j", "19086778"]}, {"Citation": "Lu X., Ji C., Xu H., Li X., Ding H., Ye M., Zhu Z., Ding D., Jiang X., Ding X., et al. Resveratrol-loaded polymeric micelles protect cells from A\u03b2-induced oxidative stress. Int. J. Pharm. 2009;375:89\u201396. doi: 10.1016/j.ijpharm.2009.03.021.", "ArticleIdList": ["10.1016/j.ijpharm.2009.03.021", "19481694"]}, {"Citation": "Wilson B., Samanta M.K., Santhi K., Kumar K.P.S., Paramakrishnan N., Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 2008;70:75\u201384. doi: 10.1016/j.ejpb.2008.03.009.", "ArticleIdList": ["10.1016/j.ejpb.2008.03.009", "18472255"]}, {"Citation": "Fasae K.D., Abolaji A.O., Faloye T.R., Odunsi A.Y., Oyetayo B.O., Enya J.I., Rotimi J.A., Akinyemi R.O., Whitworth A.J., Aschner M. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer\u2019s disease: Limitations, and current and future perspectives. J. Trace Elem. Med. Biol. 2021;67:126779. doi: 10.1016/j.jtemb.2021.126779.", "ArticleIdList": ["10.1016/j.jtemb.2021.126779", "34034029"]}, {"Citation": "Choi J.-S., Choi H.J., Jung D.C., Lee J.-H., Cheon J. Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid \u03b2 self-assembly. Chem. Commun. 2008;19:2197\u20132199. doi: 10.1039/b803294g.", "ArticleIdList": ["10.1039/b803294g", "18463738"]}, {"Citation": "Schaffazick S., Pohlmann A., de Cordova C., Creczynski-Pasa T., Guterres S. Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int. J. Pharm. 2005;289:209\u2013213. doi: 10.1016/j.ijpharm.2004.11.003.", "ArticleIdList": ["10.1016/j.ijpharm.2004.11.003", "15652213"]}, {"Citation": "Wilson B., Samanta M.K., Santhi K.K., Kumar K.S., Ramasamy M., Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer\u2019s drug tacrine. Nanomed. Nanotechnol. Biol. Med. 2010;6:144\u2013152. doi: 10.1016/j.nano.2009.04.001.", "ArticleIdList": ["10.1016/j.nano.2009.04.001", "19446656"]}, {"Citation": "H\u00e3\u00a4Rtig W., Kacza J., Paulke B.-R., Grosche J., Bauer U., Hoffmann A., Elsinghorst P.W., G\u00fctschow M., G\u00fctschow M. In vivo labelling of hippocampal \u00ce\u00b2-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. Eur. J. Neurosci. 2009;31:99\u2013109. doi: 10.1111/j.1460-9568.2009.07038.x.", "ArticleIdList": ["10.1111/j.1460-9568.2009.07038.x", "20092557"]}, {"Citation": "Skaat H., Margel S. Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-\u03b2 fibrils detection and removal by a magnetic field. Biochem. Biophys. Res. Commun. 2009;386:645\u2013649. doi: 10.1016/j.bbrc.2009.06.110.", "ArticleIdList": ["10.1016/j.bbrc.2009.06.110", "19559008"]}, {"Citation": "Pai A.S., Rubinstein I., \u00d6ny\u00fcksel H. PEGylated phospholipid nanomicelles interact with \u03b2-amyloid(1\u201342) and mitigate its \u03b2-sheet formation, aggregation and neurotoxicity in vitro. Peptides. 2006;27:2858\u20132866. doi: 10.1016/j.peptides.2006.04.022.", "ArticleIdList": ["10.1016/j.peptides.2006.04.022", "16762454"]}, {"Citation": "Manek E., Petroianu G.A. Chitosan-based nanoparticles in Alzheimer\u2019s disease: Messenger or message? Neural Regen. Res. 2021;16:2204\u20132205. doi: 10.4103/1673-5374.310685.", "ArticleIdList": ["10.4103/1673-5374.310685", "PMC8354127", "33818494"]}, {"Citation": "Boridy S., Takahashi H., Akiyoshi K., Maysinger D. The binding of pullulan modified cholesteryl nanogels to A\u03b2 oligomers and their suppression of cytotoxicity. Biomaterials. 2009;30:5583\u20135591. doi: 10.1016/j.biomaterials.2009.06.010.", "ArticleIdList": ["10.1016/j.biomaterials.2009.06.010", "19577802"]}, {"Citation": "Agyare E.K., Curran G.L., Ramakrishnan M., Yu C.C., Poduslo J.F., Kandimalla K.K. Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer\u2019s disease and Cerebral Amyloid Angiopathy. Pharm. Res. 2008;25:2674\u20132684. doi: 10.1007/s11095-008-9688-y.", "ArticleIdList": ["10.1007/s11095-008-9688-y", "PMC3766361", "18712585"]}, {"Citation": "Zhu L., Zhao Z., Cheng P., He Z., Cheng Z., Peng J., Wang H., Wang C., Yang Y., Hu Z. Antibody-Mimetic Peptoid Nanosheet for Label-Free Serum-Based Diagnosis of Alzheimer\u2019s disease. Adv. Mater. 2017;29:1700057. doi: 10.1002/adma.201700057.", "ArticleIdList": ["10.1002/adma.201700057", "28605073"]}, {"Citation": "Araya E., Olmedo I., Bastus N.G., Guerrero S., Puntes V.F., Giralt E., Kogan M.J. Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis. Nanoscale Res. Lett. 2008;3:435\u2013443. doi: 10.1007/s11671-008-9178-5.", "ArticleIdList": ["10.1007/s11671-008-9178-5"]}, {"Citation": "Patel D.A., Henry J.E., Good T.A. Attenuation of \u03b2-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment. Brain Res. 2007;1161:95\u2013105. doi: 10.1016/j.brainres.2007.05.055.", "ArticleIdList": ["10.1016/j.brainres.2007.05.055", "PMC2031224", "17604005"]}, {"Citation": "Hu B., Dai F., Fan Z., Ma G., Tang Q., Zhang X. Nanotheranostics: Congo Red/Rutin-MNPs with Enhanced Magnetic Resonance Imaging and H2O2-Responsive Therapy of Alzheimer\u2019s disease in APPswe/PS1dE9 Transgenic Mice. Adv. Mater. 2015;27:5499\u20135505. doi: 10.1002/adma.201502227.", "ArticleIdList": ["10.1002/adma.201502227", "26270904"]}, {"Citation": "Klajnert B., Cladera J., Bryszewska M. Molecular Interactions of Dendrimers with Amyloid Peptides: pH Dependence. Biomacromolecules. 2006;7:2186\u20132191. doi: 10.1021/bm060229s.", "ArticleIdList": ["10.1021/bm060229s", "16827586"]}, {"Citation": "Mondal S., Chowdhury S.R., Shah M., Kumar V., Kumar S., Iyer P.K. Nanoparticle Assisted Regulation of Nucleation Pathway of Amyloid Tetramer and Inhibition of Their Fibrillation Kinetics. ACS Appl. Bio. Mater. 2019;2:2137\u20132142. doi: 10.1021/acsabm.9b00128.", "ArticleIdList": ["10.1021/acsabm.9b00128", "35030652"]}, {"Citation": "Cabaleiro-Lago C., Quinlan-Pluck F., Lynch I., Lindman S., Minogue A.M., Thulin E., Walsh D.M., Dawson K.A., Linse S. Inhibition of Amyloid \u03b2 Protein Fibrillation by Polymeric Nanoparticles. J. Am. Chem. Soc. 2008;130:15437\u201315443. doi: 10.1021/ja8041806.", "ArticleIdList": ["10.1021/ja8041806", "18954050"]}, {"Citation": "Mondal S., Kumar V., Chowdhury S.R., Shah M., Gaur A., Kumar S., Iyer P.K. Template-Mediated Detoxification of Low-Molecular-Weight Amyloid Oligomers and Regulation of Their Nucleation Pathway. ACS Appl. Bio. Mater. 2019;2:5306\u20135312. doi: 10.1021/acsabm.9b00514.", "ArticleIdList": ["10.1021/acsabm.9b00514", "35021531"]}, {"Citation": "Cabaleiro-Lago C., Quinlan-Pluck F., Lynch I., Dawson K.A., Linse S. Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid \u03b2 Protein Fibrillation. ACS Chem. Neurosci. 2010;1:279\u2013287. doi: 10.1021/cn900027u.", "ArticleIdList": ["10.1021/cn900027u", "PMC3368671", "22778827"]}, {"Citation": "Mourtas S., Canovi M., Zona C., Aurilia D., Niarakis A., La Ferla B., Salmona M., Nicotra F., Gobbi M., Antimisiaris S. Curcumin-decorated nanoliposomes with very high affinity for amyloid-\u03b21-42 peptide. Biomaterials. 2011;32:1635\u20131645. doi: 10.1016/j.biomaterials.2010.10.027.", "ArticleIdList": ["10.1016/j.biomaterials.2010.10.027", "21131044"]}, {"Citation": "Bolade O.P., Williams A.B., Benson N.U. Green synthesis of iron-based nanomaterials for environmental remediation: A review. Environ. Nanotechnol. Monit. Manag. 2019;13:100279. doi: 10.1016/j.enmm.2019.100279.", "ArticleIdList": ["10.1016/j.enmm.2019.100279"]}, {"Citation": "Faisal S., Jan H., Shah S.A., Shah S., Khan A., Akbar M.T., Rizwan M., Jan F., Wajidullah, Akhtar N., et al. Green Synthesis of Zinc Oxide (ZnO) Nanoparticles Using Aqueous Fruit Extracts of Myristica fragrans: Their Characterizations and Biological and Environmental Applications. ACS Omega. 2021;6:9709\u20139722. doi: 10.1021/acsomega.1c00310.", "ArticleIdList": ["10.1021/acsomega.1c00310", "PMC8047667", "33869951"]}, {"Citation": "Sudhakar V., Richardson R.M. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics. 2018;16:166\u2013175. doi: 10.1007/s13311-018-00694-0.", "ArticleIdList": ["10.1007/s13311-018-00694-0", "PMC6361055", "30542906"]}, {"Citation": "Soofiyani S.R., Baradaran B., Lotfipour F., Kazemi T., Mohammadnejad L. Gene Therapy, Early Promises, Subsequent Problems, and Recent Breakthroughs. Adv. Pharm. Bull. 2013;3:249\u2013255. doi: 10.5681/apb.2013.041.", "ArticleIdList": ["10.5681/apb.2013.041", "PMC3848228", "24312844"]}, {"Citation": "Jadhav S., Avila J., Sch\u00f6ll M., Kovacs G.G., K\u00f6vari E., Skrabana R., Evans L.D., Kontsekova E., Malawska B., De Silva R., et al. A walk through tau therapeutic strategies. Acta Neuropathol. Commun. 2019;7:22. doi: 10.1186/s40478-019-0664-z.", "ArticleIdList": ["10.1186/s40478-019-0664-z", "PMC6376692", "30767766"]}, {"Citation": "Pardridge W.M. Peptide Drug Delivery to the Brain. Raven Press; New York, NY, USA: 1991. pp. 1\u2013357."}, {"Citation": "Pardridge W.M. Drug Delivery to the Brain. J. Cereb. Blood Flow Metab. 1997;17:713\u2013731. doi: 10.1097/00004647-199707000-00001.", "ArticleIdList": ["10.1097/00004647-199707000-00001", "9270488"]}, {"Citation": "Juliano R.L. The delivery of therapeutic oligonucleotides. Nucleic. Acids Res. 2016;44:6518. doi: 10.1093/nar/gkw236.", "ArticleIdList": ["10.1093/nar/gkw236", "PMC5001581", "27084936"]}, {"Citation": "Khorkova O., Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. Nat. Biotechnol. 2017;35:249\u2013263. doi: 10.1038/nbt.3784.", "ArticleIdList": ["10.1038/nbt.3784", "PMC6043900", "28244991"]}, {"Citation": "Scoles D.R., Pulst S.M. Spinocerebellar Ataxia Type 2. Polyglutamine Disord. 2018;1049:175\u2013195. doi: 10.1007/978-3-319-71779-1_8.", "ArticleIdList": ["10.1007/978-3-319-71779-1_8", "29427103"]}, {"Citation": "Bennett C.F., Krainer A.R., Cleveland D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019;42:385\u2013406. doi: 10.1146/annurev-neuro-070918-050501.", "ArticleIdList": ["10.1146/annurev-neuro-070918-050501", "PMC7427431", "31283897"]}, {"Citation": "Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367\u2013371. doi: 10.1038/nature22038.", "ArticleIdList": ["10.1038/nature22038", "PMC5642042", "28405022"]}, {"Citation": "Scoles D.R., Meera P., Schneider M.D., Paul S., Dansithong W., Figueroa K.P., Hung G., Rigo F., Bennett G.H.F.R.C.F., Otis P.M.T.S., et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362\u2013366. doi: 10.1038/nature22044.", "ArticleIdList": ["10.1038/nature22044", "PMC6625650", "28405024"]}, {"Citation": "Darras B.T., Chiriboga C.A., Iannaccone S.T., Swoboda K., Montes J., Mignon L., Xia S., Bennett C.F., Bishop K.M., Shefner J.M., et al. Nusinersen in later-onset spinal muscular atrophy. Neurology. 2019;92:e2492\u2013e2506. doi: 10.1212/WNL.0000000000007527.", "ArticleIdList": ["10.1212/WNL.0000000000007527", "PMC6541434", "31019106"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "10"}, {"Year": "2022", "Month": "7", "Day": "24"}, {"Year": "2022", "Month": "7", "Day": "26"}, {"Year": "2022", "Month": "8", "Day": "12", "Hour": "1", "Minute": "19"}, {"Year": "2022", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "28"}], "PublicationStatus": "epublish", "ArticleIdList": ["35956796", "PMC9369981", "10.3390/molecules27154839", "molecules27154839"]}}], "PubmedBookArticle": []}